InvestorsHub Logo
Post# of 252489
Next 10
Followers 7
Posts 560
Boards Moderated 0
Alias Born 03/13/2007

Re: vinmantoo post# 111518

Sunday, 12/26/2010 9:30:36 PM

Sunday, December 26, 2010 9:30:36 PM

Post# of 252489
>>Onxx is now profitable from Nexavar<<

They have lost $68m for the first 9 months of the year. If they hadn't sold Japanese rights to Carfilzomib they would have lost $127m for the first 9 months of the year.

Even non-GAAP they lost money for the first 9 months of the year. (The upfront Japanese licensing fee is obviously one-time and therefore should have not been included in non-GAAP earnings.)


>>The Japanese deal recouped about 40% of the entire Proteolix deal that brought Carfilzomib to Onxx, so I expect some nice cash coming from selling rights to the rest of Asia. I do expect Onxx to partner in Europe. The agreement with Bayer changed on Dec 20 , such that Onxx stated any buyout now will not come at the Nexavar profits.<<

What does any of that have to do with the topic we are discussing??


>>I must say you have been pretty negative towards Onxx for sometime and that hasn't been very accurate.<<

Although I have been long for some time, I am not negative or positive toward Onyx. I am realistic. Try it sometime.

micro

Life is an IQ test.

email: microcapfun@yahoo.com

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.